middle.news
Amplia gains fresh funding for narmafotinib cancer trials
1:45pm on Thursday 22nd of October, 2026 AEDT
•
Biotechnology and Pharmaceuticals
Read Story
Amplia gains fresh funding for narmafotinib cancer trials
1:45pm on Thursday 22nd of October, 2026 AEDT
Key Points
A$4.78 million R&D tax rebate received for the year ended 31 March 2026
Funds to support ACCENT, AMPLICITY, ACCENT-MINI and PRROSE programs
Rebate relates primarily to narmafotinib clinical trial expenditure
Lilly combination studies and AMP886 research also included
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE